Acute Leukemias - Republican Scientific Medical Library

a References 273
33. Ingram LC, Fairclough DL, Furman WL, et al. (1991) Cranial nerve
palsy in childhood acute lymphoblastic leukemia and non-Hodgkin’s
lymphoma. Cancer 67:2262
34. Hölzer D, Ludwig WD, Thiel E, et al. (1996) Improved outcome in
adult B-cell acute lymphoblastic leukemia. Blood 87:495–508
35. Thomas DA, Cortes J, O’Brien S, et al. (1999) Hyper-CVAD program
in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol
17:2461–2470
36. Pavlovsky S, Eppinger-Helft M, Sackmann Muriel F (1973) Factors
that influence the appearance of central nervous system leukemia.
Blood 42:935–939
37. Schlieben S, Borkhardt A, Reinisch I, et al. (1996) Incidence and
clinical outcome of children with BCR/ABL-positive acute lymphoblastic
leukemia (ALL): A prospective RT-PCR study based on 673
patients enrolled in the German pediatric multicenter therapy
trials ALL-BFM 90 and CoALL-05-92. Leukemia 10:957–963
38. Schrappe M, Arico M, Harbott J, et al. (1998) Philadelphia chromosome-positive
(Ph+) childhood acute lymphoblastic leukemia:
Good initial steroid response allows early prediction of a favorable
treatment outcome. Blood 92:2730–2741
39. Tiftik N, Bolaman Z, Batun S (2004) The importance of CD7 and
CD56 antigens in acute leukemias. Int J Clin Pract 58(2):149–152
40. Ravandi F, Cortes J, Estrov Z, et al. (2002) CD56 expression predicts
occurrence of CNS disease in acute lymphoblastic leukemia. Leukemia
Res 26:643–649
41. Pui CH, Sandlund JT, Pei D, et al. (2003) Results of therapy for acute
lymphoblastic leukemia in black and white children. JAMA
290:2061–2063
42. Stewart DJ, Keating MJ, McCredie KB, et al. (1981) Natural history
of central nervous system acute leukemia in adults. Cancer
47:187–196
43. Kantarjian HM, Walters RS, Smith TL, et al. (1988) Identification of
risk groups for development of central nervous system leukemia
in adults with acute lymphocytic leukemia. Blood 72:1784–1789
44. Kantarjian HM, Smith T, Estey E, et al. (1992) Prognostic significance
of elevated serum beta 2-microglobulin levels in adult
acute lymphocytic leukemia [see comments]. Am J Med 93:
599–604
45. Blaney SM, Balis FM, Poplack DG (1991) Current pharmacological
treatment approaches to central nervous system leukemia. Drugs
41:702–716
46. Balis FM, Poplack DG (1989) Central nervous system pharmacology
of antileukemic drugs. Am J Pediatr Hematol Oncol 11:74–86
47. Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer
Treat Rev 14:1
48. Harbaugh RE (1989) Novel CNS-directed drug delivery systems in
Alzheimer’s disease and other neurological disorders. Neurobiol
Aging 10:623
49. Bomgaars L, Geyer JR, Franklin J, et al. (2004) Phase I of intrathecal
liposomal cytarabine in children with neoplastic meningitis. J Clin
Oncol 22:3916–3921
50. Balis FM, Savitch JL, Bleyer WA, et al. (1985) Remission induction of
meningeal leukemia with high-dose intravenous methotrexate.
J Clin Oncol 3:485–489
51. Morra E, Lazzarino M, Inverardi D, et al. (1986) Systemic high-dose
ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic
leukemia and non-Hodgkin’s lymphoma. J Clin Oncol
4:1207–1211
52. Ito C, Evans WE, McNinch L, et al. (1996) Comparative cytotoxicity
of dexamethasone and prednisolone in childhood acute lymphoblastic
leukemia. J Clin Oncol 14:2370–2376
53. Balis FM, Lester CM, Chrousos GP, et al. (1987) Differences in cerebrospinal
fluid penetration of corticosteroids: Possible relationship
to the prevention of meningeal leukemia. J Clin Oncol
5:202–207
54. Relling MV, Mahmoud HH, Pui CH, et al. (1996) Etoposide achieves
potentially cytotoxic concentrations in CSF of children with acute
lymphoblastic leukemia. J Clin Oncol 14:399–404
55. Zimm S, Ettinger LJ, Holcenberg JC, et al. (1985) Phase I and clinical
pharmacological study of mercaptopurine administered as a
prolonged intravenous infusion. Cancer Res 45:1869–1873
56. Bostrom BC, Sensel MR, Sather HN, et al. (2003) Dexamethasone
versus prednisone and daily oral versus weekly intravenous mercaptopurine
for patients with standard-risk acute lymphoblastic
leukemia: A report from the Children’s Cancer Group. Blood
101:3809–3817
57. Dibenedetto SP, Di Cataldo A, Ragusa R, et al. (1995) Levels of Lasparagine
in CSF after intramuscular administration of asparaginase
form Erwinia in children with acute lymphoblastic leukemia.
J Clin Oncol 13:339–344
58. Riccardi R, Holcenberg JS, Glaubiger DL, et al. (1981) L-asparaginase
pharmacokinetics and asparagines levels in cerebrospinal
fluid of rhesus monkeys and humans. Cancer Res 41:4554–4558
59. Hawkins DS, Park JR, Thomson BJ, et al. (2004) Asparaginase pharmacokinetics
after intensive polyethylene glycol-conjugated L-asparaginase
therapy for children with relapsed acute lymphoblastic
leukemia. Clin Cancer Res 10:5335–5341
60. Pui CH, Mahmoud HH, Rivera GK, et al. (1998) Early intensification
of intrathecal chemotherapy virtually eliminates central nervous
system relapse in children with acute lymphoblastic leukemia.
Blood 92:411–415
61. Schrappe M, Reiter A, Ludwig WD, et al. (2000) Improved outcome
in childhood acute lymphoblastic leukemia despite reduced use
of anthracyclines and cranial radiotherapy: Results of trial ALL-
BFM 90. Blood 95:3310–3322
62. Pullen J, Boyett J, Shuster J, et al. (1993) Extended triple intrathecal
chemotherapy trial for prevention of CNS relapse in good-risk
and poor-risk patients with B-progenitor acute lymphoblastic leukemia:
A Pediatric Oncology Group study. J Clin Oncol 11:839–849
63. Krance RA, Newman EM, Ravindranath Y, et al. (1991) A pilot study
of intermediate-dose methotrexate and cytosine arabinoside,
“spread-out“ or “up-front,“ in continuation therapy for childhood
non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology
Group study. Cancer 67:550–556
64. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. (1998) Acute neurotoxicity
in children with B-precursor acute lymphoid leukemia: An
association with intermediate-dose intravenous methotrexate
and intrathecal triple therapy – A Pediatric Oncology Group study.
J Clin Oncol 16:1712–1722
65. Kamps WA, Bokkerink JP, Hahlen K, et al. (1999) Intensive treatment
of children with acute lymphoblastic leukemia according
to ALL-BFM-86 without cranial radiotherapy: Results of Dutch
Childhood Leukemia Study Group Protocol ALL-7 (1988–1991).
Blood 94:1226–1236
66. Tubergen DG, Gilchrist GS, O’Brien RT, et al. (1993) Prevention of
CNS disease in intermediate-risk acute lymphoblastic leukemia: